. . september 2014 (25) .eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . august 2016 (24) .despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6. . former novartis exec to lead cambridge diabetes startup semma
. september 2014 (25) .eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . august 2016 (24) .despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6. . former novartis exec to lead cambridge diabetes startup semma